News

Filter

Current filters:

TarcevaGlaxoSmithKline

1 to 9 of 17 results

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox

26-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch

21-06-2012

US oncologists surveyed by advisory firm Decision Resources say they prescribe drugs behemoth Pfizer's…

GlaxoSmithKlineHerceptinMarkets & MarketingNorth AmericaOncologyPfizerPharmaceuticalResearchRocheTarcevaTykerbXalkori

"Secret" compulsory license hearings in India for Roche's Tarceva under TRIPs rule

24-03-2008

A hearing by the Indian Patent Office to approve a compulsory license application under a rarely-used…

ApotexBoehringer IngelheimerlotinibGlaxoSmithKlineGleevecGSKImatinib MesylateNovartisRocheShireTarceva

India patent battle over Tarceva opens new CL front

21-01-2008

The latest attempt to claim a compulsory license, adopting a mechanism introduced via the World Trade…

ApotexBoehringer IngelheimerlotinibGlaxoSmithKlineGSKRocheShireTarceva

1 to 9 of 17 results

COMPANY SPOTLIGHT

Menarini

Back to top